Sanders Statement on FDA Approval of Drug to Treat Pediatric LEMS
WASHINGTON, May 8 โ Senator Sanders released the following statementย in response to news that the U.S. Food and Drug Administration approved treatment for pediatric Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder. In February, Sandersย sent a letterย to the CEO of Catalyst Pharmaceuticals,ย demanding an explanation for its decision to set the price of its drug, Firdapse, at $375,000 a year. โThis